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BACKGROUND Long lesions account for a signiﬁcant proportion of
percutaneous coronary intervention and it has been identiﬁed as one
of the predictors which inﬂuence risk of angiographic and clinical
restenosis. However, newer generation drug-eluting stents particu-
larly of long length avoid incomplete coverage of the diseased
segment of the long lesion and thereby minimize the occurrence of
restenosis. Therefore, in this LONG-FLEX registry, we aimed to assess
clinical outcomes of real-world patients who were successfully treated
with long length Supraﬂex (Sahajanand Medical Technologies Pvt.
Ltd., Surat, India), a novel biodegradable polymer coated sirolimus-
eluting stent.
METHODS This retrospective, non-randomized and observational
registry included 240 consecutive patients who were treated with long
Supraﬂex stent (length 40mm) in view of long coronary lesions from
nine different clinical sites of India. The primary endpoint of the study
was 9-month incidence ofmajor adverse cardiac events (MACE) deﬁned
as a composite of cardiac death, myocardial infarction (MI), target
lesion revascularization (TLR) and target vessel revascularization
(TVR). We also assessed stent thrombosis (ST) according to the Aca-
demic Research Consortium deﬁnition at 9-month clinical follow-up.
RESULTS The study population consisted of 240 consecutive pa-
tients who were successfully treated with long study stents between
July, 2012 and May, 2014. The study population predominantly
included high risk patients with 120 (50.0%) hypertensive patients
and 56 (23.3%) diabetic patients which reﬂected real-world scenario.
A total of 248 lesions were intervened with a total of 287 study
stents. The average number of implanted stents per lesion was
1.20.4. Clinical follow-up at 9-month was completed in 236
(98.33%) patients. At 9-month clinical follow-up, 1 (0.42%) died due
to cardiac event, 4 (1.69%) had MI and 2 (0.85%) underwent TLR.
Thus, nine-month clinical follow-up demonstrated low rate of MACE
(n¼7; 2.97%). A total of 4 (1.69%) incidences of ST, 1 (0.42%) deﬁnite
ST and 3 (1.27%) probable ST, were observed at 9-month clinical
follow-up.
CONCLUSIONS The nine-month clinical outcomes of this “real-
world” registry demonstrated safety and efﬁcacy of Supraﬂex stent in
patients receiving long study stents (stent length 40 mm) implanted
over long length coronary lesions.
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BACKGROUND Only limited long-term safety and efﬁcacy data from
large randomized clinical trials are available on second-generation
drug-eluting stents (DES). In a head-to-head comparison, we assessed
the 5-year safety and efﬁcacy of the zotarolimus eluting Resolutestent (Medtronic) versus the everolimus-eluting Xience V stent
(Abbott Vascular).
METHODS The TWENTE trial is an investigator-initiated, patient-
blinded, randomized, non-inferiority study with limited exclusion
criteria (all coronary syndromes except for STEMI), performed in a
broad patient population that reﬂects routine clinical practice. Pa-
tients (n¼1,391; 81.4% of the entire eligible patient population) were
randomly assigned to percutaneous coronary intervention (PCI) with
Resolute (n¼697) or Xience V stents (n¼694). Similarity in one-year
clinical outcome between trial participants and the non-enrolled pa-
tient population has previously been reported in detail. The primary
endpoint is target vessel failure (TVF), a composite of cardiac death,
target vessel-related myocardial infarction (MI), and target vessel
revascularization (TVR). Secondary endpoints included the individual
components of the primary endpoint and the incidence of stent
thrombosis. An independent external research organization per-
formed the clinical event adjudication.
RESULTS In the study population (64.210.8 years; 72.5% male)
non-ST-elevation acute coronary syndromes were present in 52.6%
of the patients and 21.6% of patients were diabetics. A large pro-
portion of patients was treated for complex type B2 or C lesions
(70.1%) and “off-label” indications for DES use (77.4%). The 5-year
incidence of the primary endpoint TVF and various secondary
endpoints will be presented for both DES groups. These include the
components of TVF, stent thrombosis, and various composite clin-
ical endpoints such as target lesion failure (TLF), major adverse
cardiac events (MACE), and patient-oriented composite endpoint
(POCE).
CONCLUSIONS We will report the ﬁnal 5-year outcome of patients
enrolled in the randomized TWENTE trial, which compared the
Resolute zotarolimus-eluting stent versus the Xience V everolimus-
eluting stent.
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BACKGROUND Patients with diabetes mellitus (DM) treated with
ﬁrst generation drug-eluting stents (DES) remain at higher risk of
major adverse cardiac events (MACE) and stent thrombosis (ST)
compared with non-diabetics. Long-term data on newer generation
DES in diabetics are sparse. We assess and compare the incidence of
MACE and ST at 3 y after implantation of Biolimus A9-eluting
coronary stents (BioMatrix, BioMatrix Flex) in diabetic and non-
diabetic patients.
METHODS A total of 1315 diabetic patients (408 insulin dependent
[IDDM], 907 non-insulin dependent[NIDDM]) and 4154 non-diabetic
patients received a BioMatrix or BioMatrix Flex coronary stent,
and were enrolled in e-BioMatrix, a prospective international multi-
center registry. The primary outcome measure of the present analysis
was the 3-y incidence of MACE (composite of cardiac death, myocar-
dial infarction [MI] or clinically driven target vessel revascularization
[TVR]). ARC deﬁnite or probable ST were secondary outcome
measures.
RESULTS Patients with DM were older than non-diabetics (mean age
64.610.2 vs. 62.811.1 y; p<0.001) and had a higher Charlson co-
morbidity index (2.11.6 vs 0.61.0; p<0.001). A high percentage of
49.8% presented with acute coronary syndromes. Diabetic patients
had more lesions (1.470.80 vs 1.420.76; p¼0.04), more vessels
treated (1.230.49 vs. 1.190.45; p¼0.006), and smaller stent di-
ameters (2.950.36 vs 3.00.36; p<0.001), while the total stent length
was similar. At 3y follow up (compliance 89.6%) 12.2% of DM patients
and 8.0% of non-DM patients had a MACE event (p<0.001). Patients
